Table 1 Baseline demographics and spirometry (safety set)
Glycopyrronium 50 μg o.d. (N = 327) | Tiotropium 18 μg o.d. (N = 330) | |
|---|---|---|
Mean (SD) age, years | 63.2 (7.9) | 63.7 (8.0) |
Male, n (%) | 237 (72.5) | 248 (75.2) |
Ethnicity, n (%) | ||
Caucasian | 225 (68.8) | 232 (70.3) |
Black | 0 | 0 |
Asian | 95 (29.1) | 91 (27.6) |
Native American | 6 (1.8) | 7 (2.1) |
Other | 1 (0.3) | 0 |
Severity of COPD (GOLD 2010), n (%) | ||
Mild | 0 | 1 (0.3) |
Moderate | 191 (58.4) | 193 (58.5) |
Severe | 136 (41.6) | 136 (41.2) |
Mean (SD) duration of COPD, years | 6.5 (5.1) | 6.2 (5.1) |
Baseline COPD exacerbation history*, n (%) | ||
0 exacerbations | 255 (78.0) | 247 (74.8) |
1 exacerbation | 52 (15.9) | 61 (18.5) |
≥2 exacerbations | 20 (6.1) | 22 (6.7) |
ICS use at baseline, n (%) | 163 (49.8) | 174 (52.7) |
Smoking history, n (%) | ||
Ex-smoker | 179 (54.7) | 182 (55.2) |
Current smoker | 148 (45.3) | 148 (44.8) |
Mean (SD) duration of smoking, pack-years | 39.6 (20.4) | 40.2 (21.5) |
Mean (SD) FEV1 post-bronchodilator, L | 1.5 (0.5) | 1.5 (0.5) |
Mean (SD) post-bronchodilator FEV1% predicted | 53.2 (13.1) | 53.9 (12.7) |
Mean (SD) post-bronchodilator FEV1 reversibility, % | 17.9 (13.5) | 17.6 (13.6) |
Mean (SD) post-bronchodilator FEV1/FVC, % | 47.4 (10.7) | 47.2 (10.5) |